Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,393 result(s) found. Displaying page 2,026 of 2,220.
    «« First « Previous 2022  2023  2024  2025  2026  2027  2028  2029  2030  Next» Last»»
    EudraCT Number: 2017-002332-16 Sponsor Protocol Number: RC31-16-8917 Start Date*: 2017-10-03
    Sponsor Name:Toulouse Hospital
    Full Title: Evaluation of the efficacy of injections of botulinic toxin in plantar lesions of patients suffering from localized epidermolysis bullosa simplex : double blind randomized controlled study.
    Medical condition: localized epidermolysis bullosa simplex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001238-16 Sponsor Protocol Number: CNTO1959PSO3012 Start Date*: 2019-01-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004942-14 Sponsor Protocol Number: IJB-LOB-2019 Start Date*: Information not available in EudraCT
    Sponsor Name:Institut Jules Bordet
    Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast
    Medical condition: ER-positive/HER2-negative invasive lobular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073096 Invasive lobular breast carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022486-10 Sponsor Protocol Number: MT-102-2001 Start Date*: 2010-11-02
    Sponsor Name:Myotec Therapeutics Limited
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subject...
    Medical condition: Cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001092-49 Sponsor Protocol Number: VPA-03 Start Date*: 2015-06-02
    Sponsor Name:Sahlgrenska Akademien Wallenberglaboratoriet
    Full Title: Valproic acid regulation of plasma PAI-1
    Medical condition: The fibrinolytic system
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10016611 Fibrinolytic activity increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002356-27 Sponsor Protocol Number: XCGD_MOBI1 Start Date*: 2015-10-16
    Sponsor Name:Ospedale San Raffaele
    Full Title: A multicentric, exploratory, non-randomised, non-controlled, prospective, open-label phase II, study evaluating safety and efficacy of IBU, G-CSF and Plerixafor as a stem cell mobilization regimen ...
    Medical condition: X-linked chronic granulomatous disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004076-13 Sponsor Protocol Number: 5 Start Date*: 2006-11-28
    Sponsor Name:Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset
    Full Title: Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment
    Medical condition: Patients with stage III or IV cancer in whom first and second line treatment have been given but who have tumours that are still progressing, giving symptomes. The patients must be in a fairly good...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004333-33 Sponsor Protocol Number: EMN22/54767414AMY2005 Start Date*: 2019-07-08
    Sponsor Name:European Myeloma Network
    Full Title: Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis
    Medical condition: Patients with newly diagnosed stage 3B AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001101-22 Sponsor Protocol Number: PURE Start Date*: 2021-08-23
    Sponsor Name:Amsterdam UMC
    Full Title: Study to evaluate the efficacy and side effects of Envarsus in patients who had a kidney transplantation
    Medical condition: Kidney transplant immunosupression for patients with CYP3A5*1 gene variance
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003698-24 Sponsor Protocol Number: 71254 Start Date*: 2021-09-20
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
    Medical condition: Chronic kidney disease, End-stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004812-73 Sponsor Protocol Number: BP18-1-501 Start Date*: 2022-05-16
    Sponsor Name:Leiden University
    Full Title: The influence of pharmacological conditioning with S-ketamine on pain sensitivity in patients with Fibromyalgia Syndrome
    Medical condition: Fibromyalgia Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000712-15 Sponsor Protocol Number: 001 Start Date*: 2018-12-17
    Sponsor Name:Andrew Lindford
    Full Title: Prospective Randomised Non-inferiority Nordic Frostbite Treatment Study comparing tPA and iloprost therapy
    Medical condition: frostbite; severe frostbite results in devastating injuries leading to significant morbidity from frequent distal extremity amputations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001403-33 Sponsor Protocol Number: TCTLR-101 Start Date*: 2023-06-06
    Sponsor Name:Ascendis Pharma Oncology Division A/S
    Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor...
    Medical condition: Locally advanced or metastatic solid tumor malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Trial now transitioned) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001908-17 Sponsor Protocol Number: 2021.40 Start Date*: 2022-09-05
    Sponsor Name:Leiden University Medical Center
    Full Title: Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroid (NEO-ATACT study)
    Medical condition: BRAF-mutated anaplastic thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10043745 Thyroid neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002251-42 Sponsor Protocol Number: GZ-2016-11512. Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: An open-label, single-center study on the safety and efficacy of avalglucosidase alpha in late-onset Pompe patients ≥5 years
    Medical condition: Late onset Pompe disease
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004850 10036143 Pompe's disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002036-17 Sponsor Protocol Number: NL61961.078.17 Start Date*: 2018-03-06
    Sponsor Name:Erasmus Medical Center
    Full Title: THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER
    Medical condition: (borderline) resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000171-13 Sponsor Protocol Number: P23 Start Date*: 2023-08-23
    Sponsor Name:leiden university medical center
    Full Title: SGM-101 tumor-targeted fluorescence endoscopy to enable discrimination of malignant from benign tissue in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia: a feasibility study
    Medical condition: Early rectal cancer/ big polyps with suspected T1 rectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10017947 - Gastrointestinal disorders 10038074 Rectal polyp PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000228-33 Sponsor Protocol Number: CE/17-12-06 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Saint-Pierre
    Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women
    Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002635-35 Sponsor Protocol Number: Ph2_INBRX-109_SA_CS Start Date*: 2022-02-11
    Sponsor Name:Inhibrx, Inc.
    Full Title: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
    Medical condition: Unresectable or metastatic conventional chondrosarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008734 Chondrosarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001305-23 Sponsor Protocol Number: 20190505 Start Date*: 2021-09-15
    Sponsor Name:Amgen
    Full Title: A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2022  2023  2024  2025  2026  2027  2028  2029  2030  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 02 21:17:06 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA